ArticleJB & JS open access
Effectiveness of Teriparatide (rhPTH) in Enhancing Functional Recovery After Arthroscopic Rotator Cuff Repair: A Triple-Blind Randomized Clinical Trial.
Article in JB & JS open access. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overview of Osteoporosis and Rotator Cuff Disease.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rotator cuff tears are common musculoskeletal injuries frequently requiring surgical intervention, yet retears occur at a notable rate. Teriparatide (recombinant human parathyroid hormone, rhPTH) has shown promise in animal studies for enhancing bone and tendon healing. However, limited human data exist on its clinical benefits when used adjunctively in arthroscopic rotator cuff repairs. Purpose: To investigate whether the systemic administration of teriparatide improves functional outcomes following arthroscopic rotator cuff repair in a triple-blind, randomized controlled trial (RCT). Methods: Fifty adult patients (aged 50-80 years) with degenerative rotator cuff tears were randomized (1:1) to receive daily subcutaneous injections of either teriparatide (20 μg) or placebo for 3 months after arthroscopic repair. Blinded evaluators assessed participants at baseline, 6 months, and 1 year. The primary outcome was the American Shoulder and Elbow Surgeons (ASES) score. Secondary outcomes included range of motion (ROM), Visual Analog Scale (VAS) for pain, nighttime pain, painkiller use, and magnetic resonance imaging (MRI) assessment of tendon integrity (Sugaya classification). Results: Final analyses included 43 participants (rhPTH group = 23, control group = 20). Both the rhPTH and control groups demonstrated significant within-group improvements in ASES scores, ROM, and pain scores from baseline to 1 year (p < 0.0001). However, no significant between-group differences were observed at the 6-month or 1-year follow-up for the ASES score (p = 0.87), ROM in all planes, or VAS pain scores. MRI evaluations at 1 year showed comparable retear rates (8.7% vs. 10%, p = 0.94), indicating no significant advantage of teriparatide in promoting tendon integrity. Conclusion: In this triple-blind RCT, teriparatide did not confer additional benefits over placebo in improving functional outcomes or reducing retear rates 1 year after arthroscopic rotator cuff repair. Larger RCTs that include a broader patient population are required to fully clarify the role of teriparatide in enhancing rotator cuff repair outcomes. Level of Evidence: Level II. See Instructions for Authors for a complete description of levels of evidence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.